Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track SER with free AI briefings, catalyst countdowns, and dilution alerts.

SER · Serina Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$19.4M Cash on Hand
9.6mo Cash Runway
Follow SER by email Get an email when SER reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about SER, unsubscribe in one click. Privacy

📣 What SER Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
SER-214 Parkinson's Disease Phase 1 · NCT02579473 Unknown
SER-252 (PEOZ-apomorphine) PARKINSON DISEASE (Disorder) Phase 1 · NCT07422675 Recruiting

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

SER holds $19.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $6.1M/quarter from operations, an estimated runway of 9.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 90 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SER files for a raise →

👥 Who Owns SER

Insiders 33.3% Other 5%+ holders 16.6% Institutions (32 holders) 9.8% Public and other holders 40.3%
HolderTypeShares% of sharesAs of
Gregory Bailey
Director · +3.35M options
Insider 8,564,382 32.23% 2026-06-17
Juvenescence Limited 5%+ holder (13D) 4,400,781 16.56% 2026-03-20
Sio Capital Management, LLC Institution (13G, 5%+) 2,000,000 7.53% 2026-09-30
Jay Venkatesan
Director · +15,250 options
Insider 232,294 0.87% 2026-05-22
Karen J Wilson
Director · +15,250 options
Insider 30,100 0.11% 2026-06-17
Richard Peter Marshall
Director · +15,250 options
Insider 12,183 0.05% 2026-05-19
Steven A Ledger
Chief Executive Officer, Director · +610,925 options
Insider 10,100 0.04% 2026-05-26
Stephen K. Brannan
Director · +15,250 options
Insider 1,000 0.00% 2026-07-07

Share count 26,569,458 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full SER picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SER and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.